Longeveron Inc.

LGVN

Healthcare|Biotechnology|US

$1.81

+0.10 (+5.85%)

Tangible Book / Share

$2.61

Cash / Share

$3.21

Next Earnings Report

Mar 5, 2027

EPS est. -$1.70 · Revenue est. $900.0K

Financing Filings (last 12 months)

Shelf registrations / offering prospectuses — latest Apr 17, 2026 (424B3). Possible dilution.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Jun 2026

Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.

NCT04925024

Recent Press Releases

Longeveron Announces Engagement of Lucid Capital Markets

Oct 28, 2026 · GlobeNewsWire

Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Oct 26, 2026 · GlobeNewsWire

Longeveron to Participate in Three Longevity/Aging Investment Conferences

Sep 30, 2026 · GlobeNewsWire

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Sep 16, 2026 · GlobeNewsWire

Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Sep 3, 2026 · GlobeNewsWire

Longeveron Announces 1-for-10 Reverse Stock Split

Aug 24, 2026 · GlobeNewsWire

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

Aug 19, 2026 · GlobeNewsWire

Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update

Aug 12, 2026 · GlobeNewsWire

Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition

Aug 11, 2026 · GlobeNewsWire

SEC Filings (75)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

Filed	Form	What it is	Links
Nov 5, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Nov 5, 2026	8-K	Material event	Document Index
Oct 26, 2026	8-K	Material event	Document Index
Oct 14, 2026	8-K	Material event	Document Index
Sep 23, 2026	8-K	Material event	Document Index
Sep 14, 2026	8-K	Material event	Document Index
Sep 10, 2026	SC 13G	Passive 5%+ stake	Document Index
Aug 24, 2026	8-K	Material event	Document Index
Aug 19, 2026	8-K	Material event	Document Index
Aug 13, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Aug 12, 2026	8-K	Material event	Document Index
Aug 12, 2026	10-Q	Quarterly report	Document Index
Aug 10, 2026	SC 13G	Passive 5%+ stake	Document Index
Jul 29, 2026	8-K	Material event	Document Index
Jul 14, 2026	8-K	Material event	Document Index
Jul 10, 2026	S-8	Employee stock plan	Document Index
Jul 8, 2026	8-K	Material event	Document Index
Jul 6, 2026	8-K	Material event	Document Index
Jun 5, 2026	8-K	Material event	Document Index
May 20, 2026	ARS	Annual report to holders	Document Index
May 20, 2026	DEFA14A	Proxy / shareholder vote	Document Index
May 20, 2026	DEF 14A	Proxy / shareholder vote	Document Index
May 15, 2026	SC 13G	Passive 5%+ stake	Document Index
May 13, 2026	8-K	Material event	Document Index
May 13, 2026	10-Q	Quarterly report	Document Index
May 8, 2026	8-K	Material event	Document Index
May 5, 2026	PRE 14A	Proxy / shareholder vote	Document Index
Apr 17, 2026	EFFECT		Document Index
Apr 17, 2026	424B3	Offering prospectus	Document Index
Apr 10, 2026	8-K	Material event	Document Index
Apr 10, 2026	S-1	IPO / offering registration	Document Index
Mar 25, 2026	8-K	Material event	Document Index
Mar 25, 2026	D		Document Index
Mar 24, 2026	8-K	Material event	Document Index
Mar 17, 2026	10-K	Annual report	Document Index
Mar 12, 2026	8-K	Material event	Document Index
Mar 9, 2026	8-K	Material event	Document Index
Mar 3, 2026	PRE 14A	Proxy / shareholder vote	Document Index
Feb 13, 2026	8-K	Material event	Document Index
Feb 10, 2026	SC 13G/A	Passive 5%+ stake	Document Index